Apoptosis-inducing factor (AIF) is a mitochondrial flavoprotein with NADH oxidase activity that has a vital function in healthy cells but is also an important mediator of caspase-independent programmed cell death in stressed and damaged cells. Here, we generated a truncated AIF derivative (AIF Δ100
Introduction
Recombinant immunotoxins are chimeric molecules that combine specific recognition of cancer cells with selective delivery of a potent protein toxin of plant or bacterial origin (1, 2) . Successful application in cancer patients has revived interest in these targeted therapeutics (3) (4) (5) . Nevertheless, repeated or prolonged treatment with antibody-toxins is complicated by frequent development of neutralizing antibodies directed against the toxin domain (6), prompting attempts to reduce immunogenicity of the toxin by chemical modification or elimination of immunodominant epitopes (7, 8) . Using a cytotoxic protein of human origin for immunotoxin-like molecules constitutes an alternative approach to circumvent the problem of high immunogenicity. Target cell killing by bacterial toxins such as Pseudomonas exotoxin A (ETA) is mediated by the inhibition of protein synthesis followed by the induction of apoptosis via indirect mechanisms (9, 10) . Consequently, human molecules that transmit strong proapoptotic signals are primary candidates for the development of antibody fusion proteins for cancer therapy (11, 12) .
Here, we investigated targeted delivery of recombinant human apoptosis-inducing factor (AIF) as a strategy to selectively induce tumor cell death. AIF plays an important role in caspase-independent programmed cell death, and its activation in cancer cells may be crucial for the effectiveness of a broad range of cytotoxic and antiproliferative substances (13) . AIF is a phylogenetically old flavoprotein that shares significant homology with bacterial ferredoxins and NADH oxidoreductases (14) . Transcription and translation of the mammalian AIF gene results in a 67-kDa precursor molecule, which harbors two putative mitochondrial localization signals at the NH 2 terminus. On mitochondrial import, the first 52 amino acids are cleaved off by the mitochondrial processing peptidase, resulting in a 62-kDa inner membrane-anchored form of AIF. Under physiologic conditions, this form of AIF is retained in the mitochondrial intermembrane space, where it is required for correct assembly and maintenance of the respiratory chain complex I (15) . On stimulation of cell death, AIF is cleaved further by calpains and/or cathepsins to a 57-kDa protein (16, 17) and released into the cytosol, from where it translocates to the nucleus (18, 19) . Nuclear AIF interacts with cyclophilin A to form an active DNase (20) , whereby the positively charged surface of AIF facilitates binding to DNA in a sequence-independent manner, which is essential for the apoptogenic function of AIF (21) .
We used recombinant human AIF to selectively induce cell death in tumor cells overexpressing the ErbB2 (HER2, Neu) receptor tyrosine kinase. Elevated ErbB2 levels have been found in many tumors of epithelial origin and have been shown to contribute to cellular transformation (22) , making this tumor-associated surface antigen an attractive target for specific therapies including monoclonal antibodies and antibody-derived reagents such as immunotoxins (2, 23) . Bacterially expressed AIF lacking the mitochondrial import signal of the protein was functionally active and induced apoptotic cell death on microinjection. For targeting to ErbB2-expressing tumor cells, this truncated AIF derivative (AIF Δ100 ) was fused to the ErbB2-specific single-chain Fv antibody fragment scFv(FRP5) (24) . The resulting chimeric scFv(FRP5)-AIF Δ100 fusion protein displayed specific binding to ErbB2-expressing tumor cells and, on inclusion of an endogenous protein translocation domain and addition of an endosomolytic activity, selectively killed ErbB2-expressing cancer cells.
Materials and Methods
Cell Lines and Culture Conditions Human A431 squamous carcinoma cells, MDA-MB453 and MDA-MB468 breast carcinoma cells, and Vero African green monkey kidney cells were maintained in DMEM (Cambrex) supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol/L L-glutamine, 100 units/mL penicillin, 100 μg/mL streptomycin. Murine Renca-lacZ renal carcinoma cells and Renca-lacZ/ErbB2 cells stably expressing human ErbB2 (25) were cultured in RPMI 1640 (Cambrex) containing the same supplements and 0.2 mg/mL Zeocin (all Renca-lacZ derivatives) and 0.48 mg/mL G418 (Renca-lacZ/ErbB2). All cells were cultivated at 37°C in a humidified atmosphere of air and 5% CO 2 .
Construction of AIF Derivatives A cDNA fragment encoding truncated human AIF that lacks residues 1 to 100 of the protein (AIF Δ100 ) was derived from full-length AIF cDNA from macrophages by PCR with oligonucleotides 5′-KpnI-AIF Δ100 5′-AAAAGGTACCGGGT-TAGGGCTGACACCAGAACAGAAACAGAAAAAGG-3′ and 3′ -EcoRI-AIF 5′-AAGAATTCTCAGTCTTCAT-GAATGTTGAATAGTTTGGCTACTTC-3′ as primers. Constructs for expression of antibody-AIF fusion proteins were then derived by stepwise assembly of cDNA encoding the ErbB2-specific scFv(FRP5) antibody fragment and AIF Δ100 cDNA, or scFv(FRP5) and AIF Δ100 fragments linked by a sequence encoding the translocation domain (residues 252-366) of ETA in derivatives of the bacterial expression vector pSW50 (26, 27) . The resulting plasmids pSW50-5-AIF Δ100 and pSW50-5-E-AIF Δ100 encode under the control of an isopropyl-β-D-thiogalactopyranoside (IPTG)-inducible tac promoter the 5-AIF Δ100 and 5-E-AIF Δ100 fusion proteins that consist of an NH 2 -terminal ompA signal peptide, a FLAG tag, and a hexahistidine tag provided by the vector backbone followed by scFv(FRP5) and AIF Δ100 , or scFv (FRP5), ETA 252-366 , and AIF Δ100 domains, respectively. For expression of recombinant AIF Δ100 without cell targeting domain, the AIF Δ100 cDNA fragment was reamplified with oligonucleotides 5′-NdeI-AvrI-AIF Δ 1 0 0 5′-TGTACA-TATGGGGTTAGGGCTGACACCAGAACAGAAAC-3′ and 3′-EcoRI-AIF and, after digestion with NdeI and EcoRI, inserted 5′ of sequences encoding Myc and hexahistidine tags in the bacterial expression vector pSW5 (28) , resulting in plasmid pSW5-AIF Δ100 . All constructs were verified by restriction analysis and DNA sequencing.
Bacterial Expression and Purification of Recombinant Proteins
Escherichia coli BL21(λDE3) carrying the respective expression plasmids was grown to an A 600 of 0.8 at 37°C in LB medium containing 0.1 mol/L glucose and 100 μg/mL ampicillin. Then, protein expression was induced by addition of IPTG to a final concentration of 0.5 mmol/L. Cells were harvested 2 h later by centrifugation at 6,000 × g for 15 min at 4°C. Bacterial pellets were resuspended in buffer A [0.6 mol/L NaCl, 8 mol/L urea, 2.7 mmol/L KCl, 4.3 mmol/L Na 2 HPO 4 , 1.4 mmol/L KH 2 PO 4 (pH 8.0)] and lysed in a French pressure cell (G. Heinemann). Lysates were cleared by centrifugation at 35,000 × g for 30 min at 4°C and loaded onto a Ni 2+ -NTA superflow column (Qiagen) connected to a fast protein liquid chromatography system (Amersham Biosciences). Unbound proteins were removed by washing with buffer A, and specifically bound proteins were eluted with buffer B (buffer A containing 0.25 mol/L imidazole). Fractions containing recombinant AIF proteins were identified by SDS-PAGE and immunoblotting with AIF-specific polyclonal goat antibody AIF (D-20; Santa Cruz Biotechnology) followed by horseradish peroxidaseconjugated anti-goat secondary antibody (Sigma-Aldrich) and chemiluminescent detection with the enhanced chemiluminescence kit (Amersham Biosciences). Relevant fractions were pooled, and denaturant was removed by dialysis against PBS containing 400 mmol/L L-arginine followed by dialysis against PBS. Dialyzed proteins were passed through a 0.45-μm filter (Millipore), divided into aliquots, and stored at −80°C until use.
Binding Assays DNA-binding activity of recombinant AIF derivatives was determined in gel retardation assays (29) . Intact pcDNA3 plasmid DNA or DNA fragments (2.5 μg of 1-kb DNA ladder; Invitrogen) were incubated for 30 min at room temperature with increasing amounts of purified AIF proteins before analysis by agarose gel electrophoresis (1%) in the presence of ethidium bromide to visualize the DNA. To inhibit interaction of AIF with DNA, recombinant proteins (320 ng) were preincubated with 1 unit heparin (Liquemin; Roche Pharma) for 30 min at room temperature before addition to 100 ng of plasmid DNA and agarose gel electrophoresis.
Binding of 5-AIF Δ100 and 5-E-AIF Δ100 proteins to the surface of tumor cells was investigated by fluorescence-activated cell sorting analysis. Trypsinized Renca-lacZ/ErbB2, Renca-lacZ, MDA-MB453, MDA-MB468, or A431 cells (5 × 10 5 ) were incubated with 2.5 μg of purified AIF proteins for 1 h at 4°C. Unbound proteins were removed, cells were washed, and bound proteins were detected with 1 μg of anti-FLAG antibody M2 (Sigma-Aldrich) followed by phycoerythrin (PE)-conjugated goat anti-mouse IgG secondary antibody (Jackson ImmunoResearch). Fluorescence of cells was analyzed using a FACSCalibur fluorescence-activated cell sorter (Becton Dickinson). For competition experiments, 5-E-AIF Δ100 was pretreated with a 5-fold molar excess of a recombinant ErbB2 protein fragment encompassing the scFv(FRP5)-binding epitope (28) for 30 min at room temperature before addition to A431 cells. To investigate the contribution of the positively charged AIF Δ100 domain to cell binding, 2.5 μg of 5-E-AIF Δ100 were preincubated with 10 units heparin for 30 min at room temperature before cellbinding analysis.
Immunofluorescence Analysis Cells were grown overnight in chamber slides, treated with 2.5 μg of purified 5-E-AIF Δ100 for 1 h at 37°C, washed, and incubated for another 1.5 h in fresh medium. Following fixation with 4% paraformaldehyde in PBS, cells were permeabilized with 0.1% Triton X-100 in PBS for 5 min at room temperature. Then, cells were sequentially incubated with ETA-specific polyclonal rabbit antibody (24) and Alexa Fluor 488 goat anti-rabbit IgG (Molecular Probes) in PBS containing 3% bovine serum albumin. Nucleic acids were stained with propidium iodide. Finally, the samples were analyzed with a Leica TCS SL laser scanning microscope (Leica Mikrosysteme).
Microinjection Experiments Vero cells (5 × 10 4 ) were seeded onto a 35-mm Petri dish in normal growth medium. One day later, 5-E-AIF Δ100 and AIF Δ100 proteins at a concentration of 72 μg/mL were each mixed with recombinant glutathione S-transferase (GST)-enhanced green fluorescent protein (eGFP) fusion protein, and mixtures were diluted 3:1 in PBS and microinjected into the cytosol of 100 to 140 cells per sample as described previously (12, 30) . Control cells were injected with GST-eGFP in the absence of AIF proteins. After microinjection, cells were incubated at 37°C for 48 h. Cell morphology was analyzed and eGFP-positive cells were counted at 0, 24, and 48 h by fluorescence microscopy.
Cell Viability and Apoptosis Assays Cells were seeded in 96-well plates at a density of 1 × 10 4 per well and incubated for 72 h at 37°C with varying concentrations of purified AIF proteins in triplicate in the presence or absence of 50 or 100 μmol/L of chloroquine. The relative number of viable cells in comparison with cells grown without AIF proteins was determined in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT; Sigma-Aldrich) metabolization assays as described (31) , and data were statistically evaluated using the t test. To confirm dependence of cytotoxic activity on binding to ErbB2, 5-E-AIF Δ100 was pretreated with a 5-fold molar excess of a recombinant ErbB2 protein fragment for 30 min at room temperature before addition to A431 cells.
Induction of apoptosis was measured after treatment of 2 × 10 5 A431 cells per well in 24-well plates with 1 μg/ mL 5-E-AIF Δ100 protein for 24 or 48 h in the presence of 100 μmol/L chloroquine. Control cells were treated with PBS and chloroquine. For each sample, adherent cells were detached with trypsin and combined with cells floating in the culture medium. Harvested cells were pelleted at 300 × g, washed twice with PBS, and labeled with Annexin V-FITC and propidium iodide for 20 min using the Annexin V-FLUOS staining kit (Roche Molecular Biochemicals) according to the manufacturer's recommendations. Fluorescence of cells was analyzed using a FACSCalibur fluorescence-activated cell sorter (Becton Dickinson). To investigate dependence of apoptosis induction on the activity of the positively charged AIF domain, Figure 1 . Construction and bacterial expression of chimeric AIF fusion proteins. A, schematic representation of human wild-type AIF and recombinant AIF derivatives. Truncated AIF Δ100 lacking residues 1 to 100 was expressed under the control of the IPTG-inducible tac promoter. Constructs for expression of antibody-AIF fusion proteins were derived by inserting the AIF Δ100 sequence directly downstream of the ErbB2-specific scFv antibody fragment scFv (FRP5) (5-AIF Δ100 ) or by connecting AIF Δ100 and scFv(FRP5) via the nontoxic translocation domain of ETA (residues 252-366) as a potential endosome escape sequence (5-E-AIF Δ100 ). For detection and purification, synthetic Myc (M), FLAG (F), and hexahistidine (H) tags were included in the molecules. Endogenous mitochondrial localization sequences (MLS), spacer region (S), and nuclear localization sequences (NLS) of AIF are indicated. B, bacterial expression and purification of recombinant AIF derivatives. Truncated AIF Δ100 (lanes 1 and 4) and 5-E-AIF Δ100 (lanes 2 and 5) and 5-AIF Δ100 (lanes 3 and 6) fusion proteins were expressed in E. coli and purified from bacterial lysates by Ni 2+ -affinity chromatography under denaturing conditions. After refolding, eluted fractions were analyzed by SDS-PAGE followed by Coomassie staining (lanes 1-3) or immunoblotting with AIF-specific antibody AIF (D-20) followed by horseradish peroxidase-conjugated secondary antibody and chemiluminescent detection (lanes 4-6). 5-E-AIF Δ100 was pretreated with heparin (16 units/μg 5-E-AIF Δ100 ) before addition to the cells.
Induction of Tumor Cell Death by Retargeted AIF

Results
Generation of ErbB2-Specific Antibody-AIF Fusion Proteins cDNA encoding truncated human AIF (amino acid residues 101-613; AIF Δ100 ) that lacks mitochondrial localization sequences was derived from mRNA of macrophages by reverse transcription-PCR and either fused directly to a sequence encoding the ErbB2-specific scFv antibody fragment scFv(FRP5) in the bacterial expression plasmid pSW50 or connected to the scFv sequence via the translocation domain of ETA (amino acid residues 252-366) as a potential endosome escape sequence (Fig. 1A) . Likewise, the AIF Δ100 cDNA fragment was inserted into plasmid pSW5 for bacterial expression of recombinant AIF Δ100 without cell targeting domain. In the resulting plasmids, pSW50-5-AIF Δ100 , pSW50-5-E-AIF Δ100 , and pSW5-AIF Δ100 expression of scFv(FRP5)-AIF Δ100 (5-AIF Δ100 ) and scFv(FRP5)-ETA 252-366 -AIF Δ100 (5-E-AIF Δ100 ) fusion proteins carrying NH 2 -terminal FLAG and hexahistidine tags and of truncated AIF Δ100 carrying COOH-terminal Myc and hexahistidine tags is controlled by the IPTG-inducible tac promoter. The recombinant proteins were expressed in E. coli strain BL21 (λDE3) and purified from bacterial lysates prepared in 8 mol/L urea by Ni 2+ -affinity chromatography under denaturing conditions. SDS-PAGE analysis revealed a purity of ∼80% after refolding (Fig. 1B) . Identity of the proteins was confirmed by immunoblot analysis with AIF-specific antibody (Fig. 1B) .
DNA-Binding Activity of AIF Fusion Proteins
Binding of AIF to DNA depends on the positively charged surface of the molecule and is indispensable for its apoptosisinducing activity (21) . To test whether the bacterially expressed antibody-AIF fusion proteins retained the ability to bind to DNA, gel retardation experiments were done. Increasing amounts of purified 5-E-AIF Δ100 and 5-AIF Δ100 proteins were incubated with 2.5 μg of DNA fragments (1-kb DNA ladder). Then, the electrophoretic mobility of the resulting protein-DNA complexes in a 1% agarose gel was determined. In the absence of antibody-AIF fusion proteins, the DNA fragments migrated with the expected distribution pattern ( Fig. 2A, lane 1) . Addition of purified 5-E-AIF Δ100 ( Fig. 2A, lanes 2-4) or 5-AIF Δ100 (Fig. 2A, lanes 5-7) retarded the DNA fragments substantially and in a concentrationdependent manner. Similar retardation was found after complexing pcDNA3 plasmid DNA with purified AIF Δ100 ( Fig. 2A, lanes 8 and 9) , showing that the bacterially expressed AIF derivatives retained DNA-binding ability irrespective of the inclusion of the heterologous cell binding and ETA translocation domain in the fusion proteins.
Binding of AIF Fusion Proteins to Tumor Cells Binding of 5-E-AIF Δ100 to ErbB2 on the surface of tumor cells was investigated by fluorescence-activated cell sorting analysis with murine Renca-lacZ/ErbB2 renal carcinoma cells stably transfected with a human ErbB2 cDNA construct (25) and human MDA-MB453 breast carcinoma cells endogenously expressing high levels of ErbB2 (32) . After incubation with purified 5-E-AIF Δ100 fusion protein followed by FLAG tag-specific antibody and PE-conjugated secondary antibody, strong binding of 5-E-AIF Δ100 to Renca-lacZ/ErbB2 and MDA-MB453 cells was detected (Fig. 2B) . Although less pronounced, also significant binding of the fusion protein to parental Renca-lacZ cells and human MDA-MB468 breast carcinoma cells was found, which do not express detectable ErbB2 levels. Similar results were obtained for 5-AIF Δ100 fusion protein that lacks the ETA domain (data not shown), suggesting a contribution of the AIF domain to cell binding independent of the presence of ErbB2. To investigate this possibility further, binding of untargeted AIF Δ100 and 5-E-AIF Δ100 fusion protein to Renca-lacZ/ErbB2 was investigated with or without preincubation of the proteins with the highly sulfated glycosaminoglycan heparin to prevent possible interaction of the positively charged surface of AIF with negatively charged molecules on the cell surface. Thereby, in the absence of heparin, binding of untargeted AIF Δ100 to the surface of Renca-lacZ/ErbB2 cells was comparable with that of 5-E-AIF Δ100 . However, whereas cell binding of AIF Δ100 was markedly reduced by heparin, binding of 5-E-AIF Δ100 was only marginally affected (shown as Supplementary Data). 1 This suggests that binding of the fusion protein to ErbB2-expressing cells is primarily mediated by interaction of the antibody domain with its antigen.
Effect of Chimeric 5-E-AIF Δ100 Protein on Cell Viability Induction of cell death by 5-E-AIF Δ100 was investigated in cell viability assays with Renca-lacZ/ErbB2 and ErbB2-negative Renca-lacZ cells. Cells were cultured for 72 hours with increasing concentrations of purified 5-E-AIF Δ100 protein before the proportion of viable cells in comparison with PBS-treated controls was determined in MTT assays. Thereby, independent from the expression of ErbB2, no cell killing by 5-E-AIF Δ100 was observed (Fig. 3A) . Similar results were obtained for 5-AIF Δ100 (data not shown). To test whether this lack of cell killing activity was due to insufficient intracellular uptake of antibody-AIF fusion protein, Renca-lacZ/ ErbB2 cells were treated with 5-E-AIF Δ100 , and uptake of the protein after 2.5 hours at 37°C was analyzed by confocal laser scanning microscopy using anti-ETA and secondary Alexa Fluor 488-conjugated antibodies for detection. In the majority of cells, punctuate staining within the cytoplasm was found (Fig. 3B) , suggesting efficient uptake of 5-E-AIF Δ100 and routing to vesicular structures such as endosomes. Diffuse intracellular staining indicative of cytosolic localization was not observed.
To investigate whether direct delivery of 5-E-AIF Δ100 to the cytosol could induce cell death, Vero cells were microinjected with purified 5-E-AIF Δ100 or untargeted AIF Δ100 for comparison. Recombinant GST-eGFP protein was coinjected to follow injected cells. As shown in Fig. 4A , injection with 5-E-AIF Δ100 had no effect on the cells, with cellular morphology after 30 hours indistinguishable from that of control cells injected with PBS (Fig. 4A, left and right) . Likewise, there was no decline in the number of apparently viable cells with normal morphology up to 48 hours after injection of 5-E-AIF Δ100 (Fig. 4B) . In marked contrast, a large proportion of cells injected with untargeted AIF Δ100 showed typical apoptotic morphology, including membrane blebbing and formation of apoptotic bodies after 30 hours (Fig. 4A, middle) . Another 18 hours later, 61% of cells injected with AIF Δ100 displayed apoptotic morphology or could no longer be identified as intact cells due to disintegration into small cell fragments (Fig. 4B) . These data show that recombinant AIF Δ100 can induce cell death if delivered into the cytosol of target cells. However, fusion to the NH 2 -terminal antibody domain apparently interfered with the proapoptotic activity of the AIF domain in 5-E-AIF Δ100 , preventing the induction of apoptosis on direct intracellular delivery by microinjection.
Selective Cytotoxicity of 5-E-AIF Δ100 Toward ErbB2-Expressing Tumor Cells
The results presented above indicate that cell binding by the scFv(FRP5) domain and DNA binding by the AIF Δ100 domain as a measure for AIF activity are preserved in 5-E-AIF Δ100 . In contrast, the observed entrapment of 5-E-AIF Δ100 in intracellular vesicles suggests that the translocation domain of ETA is not fully functional in the context of the fusion protein. To test whether chimeric AIF molecules ErbB2-expressing Renca-lacZ/ErbB2 (black columns) and Renca-lacZ control cells (white columns) were incubated with the indicated concentrations of purified 5-E-AIF Δ100 . After 72 h, the relative number of viable cells in comparison with PBS-treated controls was determined using an MTT metabolization assay. Bars, SD. B, uptake and intracellular localization of 5-E-AIF Δ100 protein. Renca-lacZ/ErbB2 cells were grown on coverslips, treated with 5-E-AIF Δ100 for 1 h, washed, and incubated for another 1.5 h at 37°C. Following fixation, the cells were sequentially incubated with anti-ETA and secondary Alexa Fluor 488-conjugated antibodies and analyzed by confocal laser scanning microscopy. Control cells were incubated with anti-ETA and secondary antibodies without addition of 5-E-AIF Δ100 . Nuclei were stained with propidium iodide.
can be released from such intracellular vesicles by an exogenous endosomolytic reagent, we incubated target cells with increasing concentrations of 5-AIF Δ100 or 5-E-AIF Δ100 in the presence of chloroquine and measured effects on cell viability in MTT assays. Although addition of chloroquine resulted in pronounced and concentration-dependent cytotoxicity of 5-E-AIF Δ100 toward Renca-lacZ/ErbB2 cells, this was not the case for ErbB2-negative Renca-lacZ control cells, showing dependence of this effect on recognition of ErbB2 on the cell surface (Fig. 5A) . Cytotoxicity of 5-E-AIF Δ100 toward human A431 epidermoid cancer cells endogenously expressing ErbB2 was even more pronounced but, as in the case of Renca-lacZ/ErbB2 cells, was strictly dependent on concurrent treatment with chloroquine (Fig. 5B, left) . Unexpectedly, chloroquine had no significant effect on 5-AIF Δ100 , which did not affect viability of A431 cells irrespective of the presence of the endosomolytic reagent (Fig. 5B, right) . This suggests that the ETA translocation domain in the longer 5-E-AIF Δ100 protein, while on its own not facilitating release from endosomes, contributes another function to the antibody-AIF molecule important for uptake and/or cytotoxic activity.
To investigate specificity of cell killing, 5-E-AIF Δ100 protein was pretreated with a 5-fold molar excess of a recombinant ErbB2 protein fragment (ErbB2 222 ) encompassing the scFv(FRP5)-binding epitope (28) before addition to A431 B, ErbB2-expressing human A431 epidermoid cancer cells were treated with increasing concentrations of 5-E-AIF Δ100 (left) or 1 μg/mL 5-AIF Δ100 (right) in the presence (black columns) or absence (white columns) of 100 μmol/L chloroquine. After 72 h, the relative number of viable cells in comparison with PBS-treated controls was determined using an MTT metabolization assay. C, to confirm specificity, 5-E-AIF Δ100 was pretreated with a 5-fold molar excess of recombinant ErbB2 protein (ErbB2 222 ). Binding of pretreated 5-E-AIF Δ100 (left, shaded area) and 5-E-AIF Δ100 in the absence of competitor (left, open area) to A431 cells was measured by flow cytometry. Bound 5-E-AIF Δ100 was detected by monoclonal anti-FLAG antibody M2 and PE-conjugated secondary antibody. Left, filled area, control cells were treated with primary and secondary antibodies in the absence of 5-E-AIF Δ100 . Right, shaded bar, to analyze cytotoxicity, 5-E-AIF Δ100 pretreated with recombinant ErbB2 protein was added to A431 cells at a final concentration of 1 μg/mL in the presence of 100 μmol/L chloroquine. Black column, control cells were treated with 5-E-AIF Δ100 and chloroquine in the absence of competitor. After 72 h, the relative number of viable cells was determined as described above. Bars, SD. ***, P < 0.001; **, P < 0.01; *, P < 0.05; ns, P > 0.05.
cells. This resulted in a marked reduction of cell binding (Fig. 5C , left) and cell killing (Fig. 5C, right) . To confirm that cell death observed on treatment with 5-E-AIF Δ100 was due to AIF-induced apoptosis, A431 cells were incubated in the presence of chloroquine with 1 μg/mL of the AIF fusion protein or 5-E-AIF Δ100 pretreated with heparin to block the activity of the AIF domain. Induction of apoptosis was measured by determining the percentage of Annexin V and propidium iodide double-positive cells (Fig. 6A) . After 24 hours, 28% of 5-E-AIF Δ100 -treated cells were apoptotic. Heparin significantly reduced the proapoptotic activity of the fusion protein (16% apoptotic cells), resulting in apoptosis similar to that in cells incubated without 5-E-AIF Δ100 (12% apoptotic cells). After 48 hours, this effect was even more pronounced, with 61% apoptotic cells on treatment with 5-E-AIF Δ100 in the absence and 27% apoptotic cells in the presence of heparin. As it was the case for Renca-lacZ/ ErbB2 cells (shown as Supplementary Data), 1 binding of 5-E-AIF Δ100 to ErbB2-expressing A431 cells was not affected by heparin (Fig. 6B) . Hence, the observed reduction in cell killing activity in the presence of heparin must be due to inhibition of the intracellular activity of the AIF domain. Indeed, neutralization of the positively charged AIF surface by heparin strongly inhibited DNA binding of 5-E-AIF Δ100 considered to be crucial for the proapoptotic activity of the protein (Fig. 6C ).
Discussion
During their progression to malignancy, cancer cells accumulate mutations that promote proliferation and limit their sensitivity to proapoptotic signals (33) . Radiation and chemotherapy depend on the induction of apoptosis, which explains why development of radioresistance and chemoresistance in cancer cells is frequently accompanied by a blockade of relevant proapoptotic signaling pathways (34, 35) . Introducing into such cells functional proapoptotic effector molecules may bypass endogenous resistance mechanisms and prove useful for cancer therapy. Here, we evaluated targeted delivery of recombinant AIF as a means to selectively induce cell death in tumor cells expressing the tumor-associated ErbB2 cell surface antigen. Many cytotoxic and antiproliferative substances rely for their activity at least in part on AIF (13) . AIF activation has been shown on treatment of glioma and leukemic cells with the cyclin-dependent kinase inhibitor flavopiridol (36, 37) , and release of endogenous AIF from mitochondria and nuclear translocation was shown to be crucial for cisplatin-induced apoptosis in prostate and ovarian cancer cells (38, 39) . Likewise, the activity of etoposide in combination with a histone deacetylase inhibitor against drug-resistant non-small cell lung carcinoma cells was strictly dependent on AIF (40) .
To test its suitability as an effector domain in cytotoxic antibody fusion proteins, we first generated a truncated AIF derivative that lacks the mitochondrial import signal of the protein but retains its endogenous nuclear localization signal. Microinjection of this recombinant AIF Δ100 molecule into the cytoplasm of Vero cells resulted in massive cell death, accompanied by clear signs of apoptosis such as membrane blebbing and formation of apoptotic bodies. Hence, increasing the concentration of activated AIF in the cytoplasm is sufficient to induce apoptosis without the requirement for exogenous chemotherapeutic agents, and as previously shown for an AIF fragment similar to AIF Δ100 , this effect may be further amplified by the release of endogenous AIF and cytochrome c from mitochondria (41) . For specific targeting to tumor cells, we either fused the AIF Δ100 fragment directly to the COOH terminus of the ErbB2-specific scFv(FRP5) antibody domain (5-AIF Δ100 ) or connected antibody and AIF Δ100 sequences via the translocation domain of ETA (5-E-AIF Δ100 ) as a potential endosome escape activity.
Recombinant AIF Δ100 , 5-AIF Δ100 , and 5-E-AIF Δ100 proteins formed complexes with plasmid DNA and DNA fragments in a concentration-dependent manner, as expected for functional AIF. Endogenous cellular AIF displays a strong positive electrostatic potential on its surface, which allows it to bind to DNA in a sequence-independent fashion. This is crucial for the apoptosis-inducing activity of AIF, and AIF mutants defective in DNA binding fail to induce cell death (21) . DNA binding and proapoptotic activity of 5-E-AIF Δ100 were abolished on preincubation with heparin. This shows that interaction of the chimeric protein with DNA is indeed dependent on the positive surface charge of the AIF domain and strongly indicates that induction of apoptosis by 5-E-AIF Δ100 relies on the same mechanism described for AIF.
When cell binding of the 5-E-AIF Δ100 protein was analyzed, we observed strong binding to ErbB2-expressing cancer cells, indicating that the ErbB2-specific antibody domain was functional. Nevertheless, to a lower extent, also binding to ErbB2-negative cells was observed. This was also the case for the shorter 5-AIF Δ100 protein (data not shown), ruling out nonspecific interaction with the cell surface via the ETA translocation domain of 5-E-AIF Δ100 . Instead, nonspecific binding to the cell surface could be attributed to the AIF domain because recombinant AIF Δ100 on its own was also able to bind to cells (shown as Supplementary Data). 1 This cell binding was blocked by preincubation of AIF Δ100 with heparin, suggesting electrostatic interaction of the positively charged AIF with negatively charged cell surface molecules as the underlying mechanism. A similar mechanism of cell binding was recently proposed for recombinant derivatives of HMGB2, another positively charged DNA-binding protein (29) . Importantly, despite the ability of the AIF domain to mediate cell binding on its own, 5-E-AIF Δ100 showed high selectivity for ErbB2-expressing cells. When ErbB2 was present on the target cell surface, cell binding of 5-E-AIF Δ100 was almost exclusively mediated by the ErbB2-specific antibody domain, indicated by the inability of heparin to significantly inhibit this interaction. Furthermore, cytotoxicity of 5-E-AIF Δ100 in the presence of the endosomolytic reagent chloroquine was strictly dependent on the expression of ErbB2, and binding to ErbB2-expressing cells as well as killing of such cells were markedly reduced in the presence of recombinant ErbB2 as a competitor. This shows that with respect to cell killing, the 5-E-AIF Δ100 protein displays the desired target cell specificity.
The 5-AIF Δ100 and 5-E-AIF Δ100 fusion proteins were bifunctional, displaying both binding to ErbB2-expressing tumor cells via their antibody domain and DNA binding via the AIF fragment as an indicator of AIF activity. Nevertheless, they were unable to facilitate cell killing in the absence of an exogenous endosomolytic activity. To induce DNA fragmentation and cell death, cellular AIF requires proteolytic processing, release from mitochondria into the cytosol, and translocation to the nucleus (18, 19) . Recombinant AIF Δ100 corresponds to the active cytoplasmic AIF fragment generated endogenously after stimulation of cell death and was effective in the induction of apoptosis after direct microinjection into the cytoplasm. In contrast, AIF fusion proteins targeted to cell surface receptors such as ErbB2 enter cells from the outside by receptor-mediated endocytosis, resulting in internalization into endosomes. Hence, induction of AIF-dependent apoptosis first requires release of active AIF from these vesicles into the cytoplasm. To enable endosome escape, we included residues 252 to 366 encompassing domain II of ETA in the 5-E-AIF Δ100 fusion protein. Thus, 5-E-AIF Δ100 closely resembles the primary structure of the bacterial toxin, with the cell-binding domain at the NH 2 terminus followed by the translocation domain and a cell death-inducing domain at the COOH terminus. Incorporation of ETA domain II as a central domain in antibody fusion proteins has previously been used to transport heterologous protein domains of diverse function into cells, including a DNA-binding fragment of the GAL4 transcription factor (27, 42) and protein antigens for vaccination (43, 44) . After cell binding and receptor-mediated endocytosis of the wild-type toxin, ETA domain II facilitates translocation of an enzymatically active COOH-terminal toxin fragment to the cytoplasm, where it ADP ribosylates elongation factor 2 (45) . This results in a block of protein synthesis. The enzymatically active ETA fragment is generated by the cellular protease furin, which processes a furin cleavage site located in ETA domain II (46) also present in the 5-E-AIF Δ100 protein.
Like the shorter 5-AIF Δ100 protein, 5-E-AIF Δ100 on its own was unable to induce apoptosis of ErbB2-expressing tumor cells despite inclusion of the ETA fragment. Instead, 5-E-AIF Δ100 remained trapped in intracellular vesicles after cell binding and internalization, indicating that incorporation of ETA domain II did not facilitate translocation of an active AIF fragment into the cytosol. However, in the presence of chloroquine, tumor cells were readily killed by 5-E-AIF Δ100 through induction of apoptosis, which was strictly dependent on the expression of ErbB2 on the target cell surface. Chloroquine has also been used as an endosome release agent for intracellular delivery of other cytotoxic proteins (12) . It accumulates in acidic compartments such as late endosomes and lysosomes, where it interferes with the pH equilibrium, finally leading to osmotic rupture of the vesicles (47) . Unexpectedly, chloroquine facilitated cell killing by 5-E-AIF Δ100 but not 5-AIF Δ100 lacking the ETA domain. This suggests that the ETA sequence contributed another function critical for 5-E-AIF Δ100 activity, which is most likely its furin cleavage site enabling liberation of a COOH-terminal AIF fragment from 5-E-AIF Δ100 by endogenous endosomal furin, also supported by our microinjection data. Direct injection into the cytoplasm of target cells bypasses receptor-mediated endocytosis and exposure to furin, preventing release of an active AIF fragment from 5-E-AIF Δ100 . This could explain why the fusion protein failed to induce cell death under these conditions, whereas AIF Δ100 on its own was active.
Taken together, we showed that it is feasible to use human AIF as an effector domain for immunotoxin-like molecules. AIF predominantly activates caspase-independent cell death pathways and contributes directly to large-scale DNA fragmentation. Hence, intracellular delivery of an active form of AIF could bypass and overcome inhibitory mechanisms often preventing caspase activation in tumor cells (13) . Bacterial expression of antibody-AIF fusion protein allows upscaling and production of molecularly defined material, which might be an advantage over similar approaches using gene-modified T cells for expression (48) . We identified intracellular processing of the antibody-AIF fusion protein and release from endosomes as critical features. The prototypic 5-E-AIF Δ100 protein still contains the bacterial ETA translocation domain, which could induce antibody responses in humans, albeit presumably at lower levels than full-length toxin. Hence, replacement of the ETA-derived furin cleavage site with a corresponding sequence from a human protein seems as a rational next step and may allow the generation of fully humanized molecules. The low molecular weight compound chloroquine, which is being used for the treatment of malaria and other diseases in humans (49) , can also be applied to achieve endosome release in vivo without causing severe side effects (50) . In the presence of chloroquine, the prototypic 5-E-AIF Δ100 molecule displayed highly selective cytotoxicity toward ErbB2-expressing cancer cells, holding promise for further optimization and development as a targeted therapeutic of human origin.
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